Search Our Site

News filed in:

"Clinical Research"

Australian researchers develop 10-minute cancer test

Researchers in Australia have developed a 10-minute test that can detect the presence of cancer cells anywhere in the human body, according to a newly published study. The test was developed after researchers from the University of Queensland found that cancer forms a unique DNA structure when placed in water. The test works by identifying... Read More »

Read More →

Researchers in Australia have developed a 10-minute test that can detect the presence of cancer cells anywhere in the human body, according to a newly published study. The test was developed after researchers from the University of Queensland found that cancer forms a unique DNA structure when placed in water. The test works by identifying… Read More »

[...]

Read More

E-Alerts Dramatically Cut Heart Attack Rate for People Hospitalized With A-Fib

A simple pop-up alert on a computer screen could help save the brains and hearts of many hospital-bound people with an irregular heartbeat, a new clinical trial reveals. Rates for heart attack and stroke plunged by close to 90 percent in people helped by the new program, the study found. The computer alert warns doctors... Read More »

Read More →

A simple pop-up alert on a computer screen could help save the brains and hearts of many hospital-bound people with an irregular heartbeat, a new clinical trial reveals. Rates for heart attack and stroke plunged by close to 90 percent in people helped by the new program, the study found. The computer alert warns doctors… Read More »

[...]

Read More

Treatment for Diffuse Large B-cell Lymphoma Gets FDA Fast Track Designation

The FDA has granted a fast track designation to selinexor for the treatment of patients with previously treated diffuse large B-cell lymphoma (DLBCL) who are ineligible to receive high-dose chemotherapy with stem cell rescue or chimeric antigen receptor (CAR) T-cell therapy, according to Karyopharm Therapeutics, Inc., the manufacturer of the first-in-class SINE compound.1 The designation... Read More »

Read More →

The FDA has granted a fast track designation to selinexor for the treatment of patients with previously treated diffuse large B-cell lymphoma (DLBCL) who are ineligible to receive high-dose chemotherapy with stem cell rescue or chimeric antigen receptor (CAR) T-cell therapy, according to Karyopharm Therapeutics, Inc., the manufacturer of the first-in-class SINE compound.1 The designation… Read More »

[...]

Read More

Three-drug combination improves life for cystic fibrosis patients

“Within 24 hours of taking the pill combination, patients were puffing less, their sinuses were clearer, they had more energy,” one researcher said. All newborns in the U.S. are tested for the genes that cause cystic fibrosis. There is no cure, but new medications may improve symptoms.BSIP / UIG via Getty Images A three-drug cocktail... Read More »

Read More →

“Within 24 hours of taking the pill combination, patients were puffing less, their sinuses were clearer, they had more energy,” one researcher said. All newborns in the U.S. are tested for the genes that cause cystic fibrosis. There is no cure, but new medications may improve symptoms.BSIP / UIG via Getty Images A three-drug cocktail… Read More »

[...]

Read More

Only One-Third of Trials Supporting FDA Approval of Cancer Drugs Met the ESMO-MCBS Criteria for Substantial Clinical Benefit

When the European Society of Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) was used to evaluate trials in cancer that were the basis of US Food and Drug Administration (FDA) approvals, researchers found that only one-third of the studies demonstrated a substantial clinical benefit, which was defined as grade A or grade B for... Read More »

Read More →

When the European Society of Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) was used to evaluate trials in cancer that were the basis of US Food and Drug Administration (FDA) approvals, researchers found that only one-third of the studies demonstrated a substantial clinical benefit, which was defined as grade A or grade B for… Read More »

[...]

Read More

Novartis CAR-T likely improves long-term survival and is cost-effective, study finds

Still, despite costs largely in line with the therapy’s benefits, the study’s author and another expert said reimbursement models have not kept up and need improvement. Novartis’ CAR-T therapy for acute lymphoblastic leukemia in pediatric patients appears to significantly increase survival while exerting costs to the healthcare system that are in line with its benefits,... Read More »

Read More →

Still, despite costs largely in line with the therapy’s benefits, the study’s author and another expert said reimbursement models have not kept up and need improvement. Novartis’ CAR-T therapy for acute lymphoblastic leukemia in pediatric patients appears to significantly increase survival while exerting costs to the healthcare system that are in line with its benefits,… Read More »

[...]

Read More

For Women Over 30, There May Be A Better Choice Than The Pap Smear

BSIP/UIG via Getty Images For most women under 65, a visit to the gynecologist often includes an unpleasant necessity: a Pap smear to check for cervical cancer risk. The test involves letting a doctor or nurse scrape cells from the back of the cervix, which are visually inspected for signs of abnormality. There’s a simpler... Read More »

Read More →

BSIP/UIG via Getty Images For most women under 65, a visit to the gynecologist often includes an unpleasant necessity: a Pap smear to check for cervical cancer risk. The test involves letting a doctor or nurse scrape cells from the back of the cervix, which are visually inspected for signs of abnormality. There’s a simpler… Read More »

[...]

Read More

Cancer Drug Approvals Are Speedier, But at What Cost? Safety, benefits from accelerated reviews questioned

The FDA’s breakthrough therapy designation program has led to faster approval times for cancer drugs but not necessarily better or safer drugs, according to an analysis of recent approvals. A review of cancer drugs approved from 2012 through 2017 showed that drugs receiving breakthrough therapy designation from the FDA reached the market 2 years faster... Read More »

Read More →

The FDA’s breakthrough therapy designation program has led to faster approval times for cancer drugs but not necessarily better or safer drugs, according to an analysis of recent approvals. A review of cancer drugs approved from 2012 through 2017 showed that drugs receiving breakthrough therapy designation from the FDA reached the market 2 years faster… Read More »

[...]

Read More

Researchers develop pill alternative to weight loss surgery

Researchers at Brigham and Women’s Hospital are developing a surgery in a pill that has the potential to replace invasive weight loss procedures, they say. “Bariatric surgery has been utilized increasingly over the last 15 to 20 years for weight management,” said Dr. Ali Tavakkoli, bariatric surgeon and co-director of the Brigham’s Center for Weight... Read More »

Read More →

Researchers at Brigham and Women’s Hospital are developing a surgery in a pill that has the potential to replace invasive weight loss procedures, they say. “Bariatric surgery has been utilized increasingly over the last 15 to 20 years for weight management,” said Dr. Ali Tavakkoli, bariatric surgeon and co-director of the Brigham’s Center for Weight… Read More »

[...]

Read More

This ‘metastasis-blocking’ compound may stop the spread of cancer

Using a new approach, scientists have located a compound that stops the spread of breast, pancreatic, and prostate cancers in mice. The compound — which they call metarrestin — destroys a unique structure inside the nucleus of cancer cells that can spread and form new tumors. A paper on the work — in which researchers... Read More »

Read More →

Using a new approach, scientists have located a compound that stops the spread of breast, pancreatic, and prostate cancers in mice. The compound — which they call metarrestin — destroys a unique structure inside the nucleus of cancer cells that can spread and form new tumors. A paper on the work — in which researchers… Read More »

[...]

Read More

Page 1 of 5

Categories
Archives